JNJ's TECVAYLI + TALVEY Shows 89% Risk Reduction in Earlier-Line Myeloma

What happened

Johnson & Johnson announced positive topline results from the Phase 3 MonumenTAL-6 trial, where TECVAYLI + TALVEY reduced the risk of disease progression or death by 89% and risk of death by 62% in earlier-line relapsed/refractory multiple myeloma. This is the fifth positive Phase 3 study for JNJ's multiple myeloma T-cell therapy portfolio in second line, reinforcing its leadership in immunotherapy. The data strengthens the oncology growth drivers (DARZALEX, CARVYKTI, etc.) that are critical to offsetting STELARA biosimilar erosion, which dragged Innovative Medicine growth by ~9.2% in Q1 FY2026. However, the stock still faces near-term overhangs from the CVS Caremark formulary switch on July 1, 2026, and ongoing talc litigation with a ~$3.4B reserve and management's inability to estimate further losses. The trial results improve the medium-term growth trajectory for JNJ's myeloma franchise but do not eliminate the immediate earnings risks from payer actions and legal liabilities.

Implication

The data strengthens conviction in oncology as a replacement growth driver, increasing the probability of the bull case (20% probability, $265 implied value). However, near-term catalysts (CVS switch, talc rulings) must be resolved before the thesis can upgrade. The stock's asymmetry improves modestly, but entry at $228 still lacks margin of safety against adverse legal and payer outcomes.

Thesis delta

The MonumenTAL-6 results modestly increase confidence in JNJ's ability to backfill STELARA erosion with oncology growth, but the WAIT rating remains because key catalysts (CVS July 1 switch, talc evidentiary rulings) are still pending. The bull case probability may edge up, but the base case still depends on execution. The trial data supports the existing growth narrative rather than creating a new valuation floor.